Patents Expiring in December 2037
✉ Email this page to a colleague
▶ Start for $1
Remove trial restrictions
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gilead Sciences Inc | VOSEVI | sofosbuvir; velpatasvir; voxilaprevir | TABLET;ORAL | 209195-001 | Jul 18, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | ||||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-001 | Jan 31, 2020 | RX | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | ACUTE TREATMENT OF MIGRAINE | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-002 | Jan 31, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | Y | ACUTE TREATMENT OF MIGRAINE | ||
| Eli Lilly And Co | REYVOW | lasmiditan succinate | TABLET;ORAL | 211280-003 | Dec 18, 2020 | DISCN | Yes | No | See Plans and Pricing | See Plans and Pricing | Y | Y | ACUTE TREATMENT OF MIGRAINE | ||
| Aurinia | LUPKYNIS | voclosporin | CAPSULE;ORAL | 213716-001 | Jan 22, 2021 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | TREATMENT OF PATIENTS WITH ACTIVE LUPUS NEPHRITIS | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use |
